Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders

This study has been completed.

Sponsor:

Collaborator:

National Cancer Institute (NCI)

Information provided by:

Memorial Sloan Kettering Cancer Center

ClinicalTrials.gov Identifier:

NCT00587054

First received: December 21, 2007

Last updated: May 17, 2011

Last verified: May 2011

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	May 2011
Primary Completion Date:	May 2011 (Final data collection date for primary outcome measure)